42 results
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:21pm
(Unaudited)
NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS
Company Background
Chromocell Therapeutics Corporation (“Chromocell” or the “Company … nature of all financial assets and liabilities, their carrying value approximates their fair value as of the balance sheet dates.
Stock-Based
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:15pm
(Unaudited)
NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS
Company Background
Chromocell Therapeutics Corporation (“Chromocell” or the “Company … nature of all financial assets and liabilities, their carrying value approximates their fair value as of the balance sheet dates.
Stock-Based
10-Q
2024 Q1
EX-10.3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
”) on an “at will” basis. Nothing in the Company’s policies, actions or this Agreement shall be construed to alter the “at will” nature of Executive’s status … the Company has business relationships and the nature and substance of those relationships. Proprietary Information also includes any confidential
10-Q
2024 Q1
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
, as discussed in Note 6.
CHROMOCELL THERAPEUTICS CORPORATION
NOTES TO CONDENSED FINANCIAL STATEMENTS
(Unaudited)
NOTE 1 – ORGANIZATION AND NATURE … to be presented on the balance sheets at fair value in accordance with ASC Topic 820.
Due to the short-term nature of all financial assets and liabilities
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
business. In addition, depending on the nature and timing of any such dispute, a resolution of a legal matter could materially affect our future … and the addictive nature of opioids became more apparent. The regulatory framework for pain medications has been tightened and these changes may affect our programs
424B3
64bvwi5gdtdewe 46x
16 Apr 24
Prospectus supplement
5:45pm
10-K
v2wluuac
16 Apr 24
Annual report
4:48pm
S-8
EX-4.5
c0vx4mpiydw9f
12 Apr 24
Registration of securities for employees
7:22pm
S-8
EX-4.6
mmo6q 6nte96l
12 Apr 24
Registration of securities for employees
7:22pm
8-K
EX-1.1
nzl9f huhwjwfz9p
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
8-K
EX-3.2
g3kpp6gv 00y5
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
424B4
8ahrni2u6 g5b
20 Feb 24
Prospectus supplement with pricing info
5:30pm
424B4
ldkomf
20 Feb 24
Prospectus supplement with pricing info
5:28pm